Gastrointestinal metastases in renal cell carcinoma : A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study
Copyright © 2024 Elsevier Ltd. All rights reserved..
BACKGROUND: Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood.
OBJECTIVES: To report clinical presentations, patient characteristics, therapeutic strategies, and prognosis of GIMs from RCC.
METHODS: We retrospectively collected data from RCC patients presenting GIMs, in 10 French GETUG centers, between 2000 and 2021.
RESULTS: We identified 74 patients with 87 GIMs, mostly gastric or duodenal. The median age at GIM diagnosis was 69 years and 76% of patients already had other metastases. GIMs occurred after a median duration of 5.4 years (IC95%=[4.2-7.1]) and 1.9 years (IC95%=[1.2-3.8]) from RCC diagnosis and first metastasis, respectively. GIMs were symptomatic in 52 patients (70%), with anemia in 41 patients (55%) and/or gastrointestinal bleeding in 31 patients (42%). Only 22 asymptomatic patients (30%) were fortuitously diagnosed. GIM management consisted of systemic treatment only in 29 GIMs (33%), local treatment only in 23 GIMs (26%), and both local and systemic treatment in 18 GIMs (21%). For 17 GIMs (20%), there was no therapeutic modification. After diagnosis of GIM, median overall survival was 19 months.
CONCLUSION: We report the largest retrospective cohort of GIMs in RCC patients. They should be suspected in case of anemia or gastrointestinal bleeding in any patient with a history of RCC. Their management varies widely depending on their location in the digestive tract and whether or not they are symptomatic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:199 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 199(2024) vom: 26. Feb., Seite 113534 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carneiro, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gastrointestinal Hemorrhage |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2024.113534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367323095 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367323095 | ||
| 003 | DE-627 | ||
| 005 | 20240229154929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2024.113534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM367323095 | ||
| 035 | |a (NLM)38241819 | ||
| 035 | |a (PII)S0959-8049(24)00010-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carneiro, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gastrointestinal metastases in renal cell carcinoma |b A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood | ||
| 520 | |a OBJECTIVES: To report clinical presentations, patient characteristics, therapeutic strategies, and prognosis of GIMs from RCC | ||
| 520 | |a METHODS: We retrospectively collected data from RCC patients presenting GIMs, in 10 French GETUG centers, between 2000 and 2021 | ||
| 520 | |a RESULTS: We identified 74 patients with 87 GIMs, mostly gastric or duodenal. The median age at GIM diagnosis was 69 years and 76% of patients already had other metastases. GIMs occurred after a median duration of 5.4 years (IC95%=[4.2-7.1]) and 1.9 years (IC95%=[1.2-3.8]) from RCC diagnosis and first metastasis, respectively. GIMs were symptomatic in 52 patients (70%), with anemia in 41 patients (55%) and/or gastrointestinal bleeding in 31 patients (42%). Only 22 asymptomatic patients (30%) were fortuitously diagnosed. GIM management consisted of systemic treatment only in 29 GIMs (33%), local treatment only in 23 GIMs (26%), and both local and systemic treatment in 18 GIMs (21%). For 17 GIMs (20%), there was no therapeutic modification. After diagnosis of GIM, median overall survival was 19 months | ||
| 520 | |a CONCLUSION: We report the largest retrospective cohort of GIMs in RCC patients. They should be suspected in case of anemia or gastrointestinal bleeding in any patient with a history of RCC. Their management varies widely depending on their location in the digestive tract and whether or not they are symptomatic | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Gastrointestinal Hemorrhage | |
| 650 | 4 | |a Gastrointestinal Tract | |
| 650 | 4 | |a Metastasis | |
| 650 | 4 | |a Renal Cell Carcinoma | |
| 700 | 1 | |a Vinceneux, A |e verfasserin |4 aut | |
| 700 | 1 | |a Larroquette, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rony, M |e verfasserin |4 aut | |
| 700 | 1 | |a Carril, L |e verfasserin |4 aut | |
| 700 | 1 | |a Laguerre, B |e verfasserin |4 aut | |
| 700 | 1 | |a Blazevic, I |e verfasserin |4 aut | |
| 700 | 1 | |a Bartelemy, P |e verfasserin |4 aut | |
| 700 | 1 | |a Teyssonneau, D |e verfasserin |4 aut | |
| 700 | 1 | |a Goujon, M |e verfasserin |4 aut | |
| 700 | 1 | |a Linassier, C |e verfasserin |4 aut | |
| 700 | 1 | |a Thiery-Vuillemin, A |e verfasserin |4 aut | |
| 700 | 1 | |a Roubaud, G |e verfasserin |4 aut | |
| 700 | 1 | |a Mourey, L |e verfasserin |4 aut | |
| 700 | 1 | |a Albiges, L |e verfasserin |4 aut | |
| 700 | 1 | |a Gravis, G |e verfasserin |4 aut | |
| 700 | 1 | |a Gross-Goupil, M |e verfasserin |4 aut | |
| 700 | 1 | |a Cancel, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 199(2024) vom: 26. Feb., Seite 113534 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:199 |g year:2024 |g day:26 |g month:02 |g pages:113534 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2024.113534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 199 |j 2024 |b 26 |c 02 |h 113534 | ||